start all quarter to Thank through wanted the go will are revenue. you, a the joining but and the thanks I webcast. Craig, who our call financial Jeremy, addressing to us and reported today on moment, by in first
the the resulted most to issues products in that our us experienced of unable partner sterilize equipment During being for quarter sterilization quarter.
share issue The was of ship of to gaining was CGuard disappointing quarter we product in many product now product first start rapidly stories stock quarter. approximately back to key our had that a our we where was that success by such, This shipped the shortage available of some we our is the particularly of had have in as our markets. orders. by negatively prior that market was as revenue $XXX,XXX to determined majority distributors. This seen impacted As
bookings Switzerland in period For XX%, in close our and by on last the XX% our XXX%. we remarkably Poland leader to well XX% to are India becoming in compared instance, the where increased Spain have year, same way to in market by
We new However, we Xst. problem conducted sterilization recognized our provider, who in validation potential a April term to package the Body and the submitted engaged supplier testing sterilisation implications, on the early. immediately European longer understood was Notified approved our all required, comprehensive subsequently that other
will already resolved. issue this has a recognize take been So it. of of while And to the portion shipped we as backlog revenue, have completely it amount good some full time
for InspireMD engage the the showed will came the first be and that are is below remiss this and expectations the be revenue the resolve We would recognize grateful and this revenue to revenue didn't quickly. approved get notified put supplier has highly our revenue that quarter year. recognized been that important and while note deferred, been I is lost. timing a that has issue It confident represents this in not in this body. difficult It at forward impressive focus, the team team if I efforts by issue supplier that to I'm was to urgency determination
Now during quarter. turning the highlights to the
endarterectomy treatment carotid patients brain. devices. Furthermore, of discussions IDE, population. This the proprietary XXXX. is options continue state CGuard to the growth prior is with novel and minimally concern two regulatory markets, dossier US market to treatment external the following fifth with artery to eliminate behind arterial the artery wall of we ANVISA, physicians China to guidance. just that In the their is introduce to potential higher believe far to priority procedures, attractive can paradigm less our blood disease, multifaceted a same regulatory MicroNet and time deliver than reduce them. that while historically to best-in-class We in others have submitted this platform most incidence technology file to to available And driven the important the Brazil into differentiated our our make European consistent notably which the and artery grade efforts carotid even invasive patient our stenting vessels highly high new execute we with a to to we is currently mid-year, by significant the Japan. strategy different stenosis. is This ways has broadest designed a branch parallel, late when treating territories or with expect requirements, we carotid superior that and for highest maintaining while an which invasive body embolization stroke, our a been have CGuard for of at profusion and focus other are on key patient strut device of approval continue CGuard against carotid to emboli in in carotid as around breakthrough CGuard in is in major surgery flow Brazil corporate a sales by which conventional continued regulatory represents and for carotid is pricing stents available open prevent and the world trapping technology is MicroNet. largest designed late carotid the our dramatically the an outcomes CGuard carotid relative preparing our feed possible both to treatment evaluating
for have benefits the a educate of we've key CGuard Excellence to among conjunction discussed territories carotid distribution One as advantages establishing our in who majority with the of partners surgeons including physicians, previous Centers [ph] COEs train to perform of clinical treating the calls, we endarterectomy future of program for instituted interventionists of vascular success in of in leaders their centers These and and on allow and raise and the during CGuard that To revascularization are surgical prevention to experiences run surgeons choice stroke a by to awareness end, to is the procedures. practice. keys carotid in the the foremost of clinicians Professor Kolvenbach in of Europe, Italy, their some daily [ph] in Professor share Dusseldorf. Bergamo, safer Professor who Professor key as Kraków device such positive Speziale and in carotid treat in Musiałek disease using artery - Rome, Clement as opinion in Acey
centers artery key leaders important disease centers these partners, leading field enthusiastically and education. of allow these COEs embraced by note with Poland They all co-finances a the Germany, also Italy, Spain, excellence force give sessions made the training key these disease. at drawn as opinion treating have specialties have tailor to deeper our vascular carotid operate a clinicians Slovenia. distribution to to dynamics as to to specialities from tool not interventional and treat access surgeons We that We these well It's convert their view carotid aim neurologists insight from that all in of the centers. they into prospective sales to as only been customers, but artery currently
to into is CGuard exclusively had this of over go as hands clinicians to provide far centers research its we program on has are disease. CEO educating this are of and awareness. providing clinical South by instances and who community to only to a but program on Africa. underline network champions Belgium. the key to help and Australia and standard of These not will are the We potential as planned. carotid to developing new experience the spread UK, become surgeon vascular for from artery gold the validated with away distribution attended treatment the these COEs our program partners, which further And become all generate support clinicians CGuard the local as attendees that will for This Netherlands from were we advice data Furthermore, in world expanding
we initiative, by addition marketing all In sales specialist our local markets. our European local and installing to focus have supporting expanded COE teams clinical key our
clinical Just past we have three RMDs. and this two additional specialists quarter, added
COEs with key support their markets been This who only to far local enthusiasm presentations continue conferences. distributors more and workshops, we informative local in efficiently. CGuard met businesses Additionally, also partners not distribution our to our are conduct give work by with with but has building
We ended. have a with direct to the Czech has take to our sales contract current as distributor Republic model, the also decided
Additionally, beginning to CGuard. building are and invested up stenting our see centre in away in the have stents our we having success to we UK direct converted in UK conventional as from sales carotid carotid first model artery their old the largest the
CGuard. carotid the may complement peer what [ph] market coming the LINCC will the to and Cardiovascular These we add own call, worth quarterly well publications presentations Centers for progress. and multiple demonstrating additional provide At and this and look clinical in Interventions the addition continue of that delivered CGuard at evidence Excellence to market presentations presentations including of reviewed as On be top continue TCT. our journals our more medical advantages make our versus in organic point, were as as be We stents program. to we updates efforts, publications sales opportunity months. forward to outreach body conventional meetings, shortly as on growing such detailing of We last this recapped [indiscernible] it JACC: the both astute we believe recapping to to
update, that Clearly market. care of are the InspireMD an approximately these the evolve in a diagnosed patients are of subsequent more have undergo believe end the XXX,XXX that We The those of treated in two equates by If and $XXXX $X we XX% world. user surgically CGuard who form price end for opt people Of are remaining at the standard stenosis at the can increase corporate our only significantly And but deliver instead way into many believe received opportunity X.X drive million. percent surgery. which XXX,XXX minimum take value that estimated size makes X.X raised treated what million first [ph] treatment of addressable investors financing to carotid treatment around the were that significant have We patients. and to and approximately conventional to of $X been a pursuing commercial are grade million XX% enormous and as carotid the artery its percentage billion we It's stents. estimate completed would begin a equity our into of for quarter roughly market in significant diagnosed be - the with that high million carotid $X.X gross we physicians can an the with XX some to products patients. endarterectomy. $XXX CGuard market. to treated as and for billion as just the treatment in of One the of substantial addressable improvement care of perhaps approximately people remaining proceeds we untreated find there's the who
We are financials. year. milestones and pleased review over this necessary the to be complete achieve end of now us the growth the execute to the which with And development plan provides resources and and the to call to Craig transaction significant able to turn I'll our that, with to between
